Animal models in drug development for MRSA.

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• A key challenge in drug discovery is correlating in vitro activity with clinical efficacy.
• Establishing a link between in vivo target engagement and therapeutic benefit is essential.
• Antibacterial drug discovery benefits from direct bacterial targets, simplifying in vitro assessment.

Purpose of the Study:

• To highlight the value of animal infection models in antibacterial drug discovery.
• To describe the advantages, methods, and outcome measurements of rodent models for Staphylococcus aureus (S. aureus) drug discovery.
• To focus on mouse models due to their cost-effectiveness and common use, while also including a rat model.

Main Methods:

• Utilizing established rodent infection models for Staphylococcus aureus.
• Focusing on mouse models as the primary economical and widely used option.
• Incorporating a rat infection model for broader applicability.

Main Results:

• Animal models serve as a predictive bridge between in vitro findings and early clinical evaluation.
• Rodent models have been successfully developed for Staphylococcus aureus infections.
• Mouse models are economical and commonly used, with rat models also available.

Conclusions:

• Animal infection models are highly valuable and predictive for antibacterial drug discovery.
• Rodent models, especially for Staphylococcus aureus, effectively bridge in vitro results and clinical potential.
• The described models aid in evaluating compound efficacy at infection sites and achieving therapeutic levels.